Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity (Q73507187)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12798707%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12798707%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12798707%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

Peter G Rose

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12798707%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Nancy Fusco

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12798707%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Mary Smrekar

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12798707%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Kim Mossbruger

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12798707%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 June 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12798707%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12798707%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12798707%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12798707%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

429-433

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12798707%20AND%20SRC:MED&resulttype=core&format=json

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Clinical features of hypersensitivity reactions to carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

A modified, prolonged desensitization protocol in carboplatin allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Hypersensitivity reactions to carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Death from anaphylaxis to cisplatin: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900178-1

7 January 2021

10.1016/S0090-8258(03)00178-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12798707%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference